Fennec Pharmaceuticals (FENC) Accumulated Expenses (2010 - 2026)
Fennec Pharmaceuticals' (FENC) quarterly Accumulated Expenses came in at $5.6 million in Q4 2025, up 64.38% YoY from $3.4 million in Q4 2024, and up 343.35% on a QoQ basis from $1.3 million in Q3 2025.
Fennec Pharmaceuticals (FENC) Accumulated Expenses (2010 - 2026) Analysis & Trends
Fennec Pharmaceuticals (FENC) has 16 years of Accumulated Expenses data on file, last reported at $5.6 million in Q4 2025.
- Quarterly Accumulated Expenses rose 64.38% year-over-year to $5.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.6 million (up 64.38% YoY) and the FY2025 annual result came in at $5.6 million, up 64.38% from the prior year.
- Accumulated Expenses advanced to $5.6 million in Q4 2025, from $1.3 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $5.6 million in Q4 2025 to a low of $171000.0 in Q2 2021.
- A 5-year average of $1.5 million and a median of $1.0 million in 2023 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses sank 70.35% — and 2023, when it soared 1343.85%.
- Tracing FENC's Accumulated Expenses over 5 years: stood at $877000.0 in 2021, then slumped by 70.35% to $260000.0 in 2022, then soared by 1343.85% to $3.8 million in 2023, then retreated by 8.68% to $3.4 million in 2024, then surged by 64.38% to $5.6 million in 2025.
- The last three Accumulated Expenses figures came in at $5.6 million (Q4 2025), $1.3 million (Q3 2025), and $1.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Fennec Pharmaceuticals | 410.60 Mn | 369.35 Mn | 17.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.70 Mn |
| Dec 31, 2025 | 5.64 Mn |
| Sep 30, 2025 | 1.27 Mn |
| Jun 30, 2025 | 1.27 Mn |
| Mar 31, 2025 | 1.27 Mn |
| Dec 31, 2024 | 3.43 Mn |
| Sep 30, 2024 | 2.32 Mn |
| Jun 30, 2024 | 2.02 Mn |
| Mar 31, 2024 | 1.62 Mn |
| Dec 31, 2023 | 3.75 Mn |
| Sep 30, 2023 | 937,000.00 |
| Jun 30, 2023 | 773,000.00 |
| Mar 31, 2023 | 1.07 Mn |
| Dec 31, 2022 | 260,000.00 |
| Sep 30, 2022 | 394,000.00 |
| Jun 30, 2022 | 294,000.00 |
| Mar 31, 2022 | 412,000.00 |
| Dec 31, 2021 | 877,000.00 |
| Sep 30, 2021 | 860,000.00 |
| Jun 30, 2021 | 171,000.00 |